Ryoji Ishida

2.7k total citations
49 papers, 2.4k citations indexed

About

Ryoji Ishida is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Ryoji Ishida has authored 49 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Molecular Biology, 13 papers in Organic Chemistry and 11 papers in Oncology. Recurrent topics in Ryoji Ishida's work include Cancer therapeutics and mechanisms (25 papers), DNA Repair Mechanisms (12 papers) and DNA and Nucleic Acid Chemistry (12 papers). Ryoji Ishida is often cited by papers focused on Cancer therapeutics and mechanisms (25 papers), DNA Repair Mechanisms (12 papers) and DNA and Nucleic Acid Chemistry (12 papers). Ryoji Ishida collaborates with scholars based in Japan, United States and United Kingdom. Ryoji Ishida's co-authors include Taijo Takahashi, T Andoh, Toshiwo Andoh, Manuel Buchwald, K Tanabe, Yoji Ikegami, Joaquím Roca, J C Wang, James M. Berger and Makoto Sato and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Cell Biology.

In The Last Decade

Ryoji Ishida

48 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ryoji Ishida Japan	23	2.0k	680	373	365	248	49	2.4k
Andrzej Składanowski Poland	27	2.1k 1.0×	1.1k 1.6×	283 0.8×	548 1.5×	141 0.6×	62	2.9k
Nives Carenini Italy	27	1.4k 0.7×	934 1.4×	196 0.5×	452 1.2×	117 0.5×	62	2.1k
Stella Tinelli Italy	27	1.6k 0.8×	1.1k 1.7×	295 0.8×	343 0.9×	82 0.3×	51	2.3k
Robert J. Hickey United States	31	2.7k 1.3×	854 1.3×	102 0.3×	294 0.8×	253 1.0×	103	3.3k
Katherine A. Kennedy United States	23	1.0k 0.5×	428 0.6×	194 0.5×	247 0.7×	261 1.1×	45	2.0k
Jan M. Woynarowski United States	24	1.5k 0.7×	1.5k 2.2×	134 0.4×	414 1.1×	78 0.3×	56	2.8k
Valentina Zuco Italy	27	1.8k 0.9×	579 0.9×	176 0.5×	420 1.2×	106 0.4×	70	2.4k
Linda H. Malkas United States	29	2.3k 1.1×	866 1.3×	102 0.3×	178 0.5×	197 0.8×	95	2.8k
John A. Double United Kingdom	25	1.7k 0.8×	423 0.6×	163 0.4×	376 1.0×	71 0.3×	75	2.5k
Zhong-Yin Zhang United States	36	2.2k 1.1×	523 0.8×	164 0.4×	238 0.7×	240 1.0×	53	2.8k

Countries citing papers authored by Ryoji Ishida

Since Specialization

Citations

This map shows the geographic impact of Ryoji Ishida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryoji Ishida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryoji Ishida more than expected).

Fields of papers citing papers by Ryoji Ishida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryoji Ishida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryoji Ishida. The network helps show where Ryoji Ishida may publish in the future.

Co-authorship network of co-authors of Ryoji Ishida

This figure shows the co-authorship network connecting the top 25 collaborators of Ryoji Ishida. A scholar is included among the top collaborators of Ryoji Ishida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryoji Ishida. Ryoji Ishida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Katsumata, Noriyuki, Yasuhiro Fujiwara, Toshiharu Kamura, et al.. (2008). Phase II Clinical Trial of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having a Therapeutic History of Platinum-based Chemotherapy: A Phase II Study of the Japanese Gynecologic Oncology Group. Japanese Journal of Clinical Oncology. 38(11). 777–785. 29 indexed citations

TAKASAKI, Masaya, Fumio Mizuno, Ryo Kobayashi, et al.. (2002). Antitumor activity of a phenoxazine compound, 2-amino-4,4α-dihydro-4α,7-dimethyl-3H-phenoxazine-3-one against human B cell and T cell lymphoblastoid cell lines: induction of mixed types of cell death, apoptosis, and necrosis. Journal of Cancer Research and Clinical Oncology. 128(7). 363–368. 34 indexed citations

Iguchi, Kazuhiro, et al.. (2001). Phosphatidylserine induces apoptosis in adherent cells. APOPTOSIS. 6(4). 263–268. 15 indexed citations

Nishida, Keiko, Masao Seto, & Ryoji Ishida. (2001). Different Susceptibilities of Postmitotic Checkpoint‐proficient and ‐deficient Balb/3T3 Cells to ICRF‐193, a Catalytic Inhibitor of DNA Topoisomerase II. Japanese Journal of Cancer Research. 92(2). 193–202. 10 indexed citations

Tomoda, Akio, Sadao Arai, Ryoji Ishida, Takashi Shimamoto, & Kazuma Ohyashiki. (2001). An improved method for the rapid preparation of 2-Amino-4,4a-dihydro-4a,7-dimethyl-3H-phenoxazine-3-one, a Novel Antitumor Agent. Bioorganic & Medicinal Chemistry Letters. 11(8). 1057–1058. 16 indexed citations

Mori, Hiroshi, et al.. (2000). Antitumor activity of 2-amino-4,4α-dihydro-4α, 7-dimethyl-3H-phenoxazine-3-one against Meth A tumor transplanted into BALB/c mice. Anti-Cancer Drugs. 11(8). 653–657. 20 indexed citations

Hamatake, Motoharu, Kazuhiro Iguchi, K. Hirano, & Ryoji Ishida. (2000). Zinc Induces Mixed Types of Cell Death, Necrosis, and Apoptosis, in Molt-4 Cells. The Journal of Biochemistry. 128(6). 933–939. 56 indexed citations

Iguchi, Kazuhiro, et al.. (1999). Decreased thymosin β4 in apoptosis induced by a variety of antitumor drugs. Biochemical Pharmacology. 57(10). 1105–1111. 34 indexed citations

Iwai, Miwako, Akira Hara, Toshiwo Andoh, & Ryoji Ishida. (1997). ICRF‐193, a catalytic inhibitor of DNA topoisomerase II, delays the cell cycle progression from metaphase, but not from anaphase to the G1 phase in mammalian cells. FEBS Letters. 406(3). 267–270. 23 indexed citations

10.

Mori, Hiroshi, et al.. (1997). Irreversible cytotoxic effect of a novel lowly immunosuppressive antitumor fluorouridine derivative, UK-21. Anti-Cancer Drugs. 8(5). 482–488. 1 indexed citations

11.

Andoh, Toshiwo, et al.. (1997). Effects of ICRF-193, a catalytic inhibitor of DNA topoisomerase II, on sister chromatid exchange. Anti-Cancer Drugs. 8(6). 637–642. 1 indexed citations

12.

Sato, Makoto, Ryoji Ishida, Keita Ohsumi, Toshiharu Narita, & Toshiwo Andoh. (1997). DNA Topoisomerase II as the Cellular Target of a Novel Antitumor Agent ICRF-193, a Bisdioxopiperazine Derivative, inXenopusEgg Extract. Biochemical and Biophysical Research Communications. 235(3). 571–575. 8 indexed citations

13.

Ishida, Ryoji, Hidehiko Kawai, Hiroshi Ito, et al.. (1996). Antitumor activity of 2-amino-4,4α-dihydro-4α, 7-dimethyl-3H-phenoxazine-3-one, a novel phenoxazine derivative produced by the reaction of 2-amino-5-methylphenol with bovine hemolysate. Anti-Cancer Drugs. 7(5). 591–595. 15 indexed citations

14.

Andoh, T, Makoto Sato, Tetsuharu Narita, & Ryoji Ishida. (1993). Role of DNA topoisomerase II in chromosome dynamics in mammalian cells. Biotechnology and Applied Biochemistry. 18(2). 165–174. 23 indexed citations

15.

Ishida, Ryoji & Kazuhiko R. Utsumi. (1990). Differences in induction of sister chromatid exchanges in MNNG-resistant Hela S3 Mer⁻cell lines. Carcinogenesis. 11(7). 1209–1212. 10 indexed citations

16.

Ishida, Ryoji, Kazuhiko R. Utsumi, & Taijo Takahashi. (1989). Sister-chromatid exchanges (SCEs), cell survival and mutation in HeLa S3 cells with different sensitivity to alkylating agents; evidence that SCE induction and cell survival or mutation induction are dissociable. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 215(1). 69–77. 1 indexed citations

17.

Ishida, Ryoji, et al.. (1989). Biochemical and genetic analysis of toxic effect of HOE 15030 in mammalian cells. Somatic Cell and Molecular Genetics. 15(4). 279–288. 1 indexed citations

18.

Ishida, Ryoji, Miwako Nishizawa, Takeharu Nishimoto, & Taijo Takahashi. (1988). Cross-resistance of novobiocin-resistant BHK cell line to topoisomerase II inhibitors. Somatic Cell and Molecular Genetics. 14(5). 489–497. 5 indexed citations

19.

Ishida, Ryoji & Taijo Takahashi. (1988). Increased O⁶-methylguanine-DNA methyltransferase activity and reduced mutability in 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-resistant HeLa S3 cells. Carcinogenesis. 9(6). 1079–1083. 4 indexed citations

20.

Matsuki, A, et al.. (1977). [Effect of methylprednisolone on plasma antidiuretic hormone (ADH) and catecholamines (CA) concentrations during hemorrhagic shock].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 26(4). 406–15. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact